Robin Mansukhani
Amministratore Delegato presso Deciduous Therapeutics, Inc.
Profilo
Robin Mansukhani is the founder of Alzeca Biosciences, Inc. He is currently the Chief Executive Officer & Director at Deciduous Therapeutics, Inc.
Posizioni attive di Robin Mansukhani
| Società | Posizione | Inizio |
|---|---|---|
Deciduous Therapeutics, Inc.
 Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | Amministratore Delegato | - |
Precedenti posizioni note di Robin Mansukhani
| Società | Posizione | Fine |
|---|---|---|
Alzeca Biosciences, Inc.
 Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | Fondatore | 01/01/2012 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | Commercial Services |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Robin Mansukhani
